Halozyme Therapeutics (HALO) Work In Process (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Work In Process data on file, last reported at $35.0 million in Q1 2026.

• Work In Process for Q1 2026 came in at $35.0 million, down 4.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.0 million (down 4.4% YoY), and the FY2025 annual result was $30.9 million, up 2.49% from the prior year.
• Work In Process climbed to $35.0 million in Q1 2026 per HALO's latest filing, from $30.9 million in the prior quarter.
• Over five years, Work In Process peaked at $56.2 million in Q3 2022 and troughed at $6.3 million in Q1 2022.
• A 5-year average of $34.9 million and a median of $35.0 million in 2026 frame the typical range for Work In Process.
• The sharpest annual moves came in 2022 and 2023: Work In Process sank 67.43% in 2022, then soared 332.75% in 2023.
• A 5-year view of Work In Process shows it stood at $44.1 million in 2022, then decreased by 22.85% to $34.0 million in 2023, then declined by 11.33% to $30.2 million in 2024, then climbed by 2.49% to $30.9 million in 2025, then gained by 13.32% to $35.0 million in 2026.
• Business Quant data shows HALO's Work In Process at $35.0 million in Q1 2026, $30.9 million in Q4 2025, and $34.8 million in Q3 2025.